Ceruvia Lifesciences
Phase II2 active candidates2 trials
shared compound: Psilocybinsame indication: Obsessive-Compulsive Disorder (OCD)Phase II peersimilar active pipeline size
Back to StakeholdersProgramme tracker View landscape
Lead program: Phase II
Categories
1 domain / 2 areas / 1 specialization
MSICS Pharma
Data updated
1 Drug Candidate
MSICS Pharma is an Israeli biotechnology company that operates a GMP production facility for naturally-sourced psilocybin. Their lead candidate MSX-06, a naturally-sourced psilocybin formulation, is in Phase 2 clinical development targeting treatment-resistant depression and obsessive-compulsive disorder.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Phase II
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
MSICS Pharma - MSX-06
Jun 26, 2026 - company-website - MSICS Pharma - MSX-06 (Natural Psilocybin GMP)
Next known catalyst
No next milestone forecast yet.
3 sources0 pipeline-linked trials0 pipeline-linked papers
Development Programmes
1MSX-06 (Natural Psilocybin GMP)
PsilocybinPhase II
Treatment-resistant depression / OCD / anxiety / eating disorders / PTSD
Programme Tracker
Treatment-Resistant Depression (TRD)
Primary: Other
Phase IIActive
Israeli Ministry of Health approved clinical trial for OCD and depression; Phase 2 recruiting; PTSD study call for proposals in review; GMP production facility operational in Ness Ziona
Milestones
Company milestone
In progressPTSD clinical study call for proposals using MSX-06 — moved into review and selection phase
Why it matters: Expanding MSX-06 indications beyond depression/OCD into PTSD. Israel's military population provides a large PTSD patient base for clinical recruitment.
Watch next: PTSD study site selection; Phase 2 OCD/depression enrollment milestones; international expansion plans
Company milestone
CompletedActual: Jan 1, 2022
MSiCS Pharma founded in Ness Ziona, Israel; GMP production facility for naturally-sourced (mushroom-derived) psilocybin established
Why it matters: MSiCS differentiates by producing naturally-sourced psilocybin via GMP mushroom cultivation rather than chemical synthesis. Leveraging Israel's progressive cannabis regulatory framework as a model for psilocybin clinical development.
Funding milestone
CompletedActual: Jan 1, 2023
$500K seed round from Fusion VC and GlenRock Israel
Why it matters: Very early-stage capitalization. Modest seed funding but sufficient for Israeli regulatory pathway and GMP facility setup. Eyal Gura (co-founder of Zebra Medical Vision) is connected as investor/advisor.
regulatory-designation
CompletedActual: Jan 1, 2024
Israeli Ministry of Health approval for clinical trial testing MSX-06 for OCD and depression
Why it matters: Israeli MOH clinical trial approval enables Phase 2 recruitment. Israel serves as a "pharmaceutical beta-site" with faster regulatory timelines than FDA/EMA — successful Israeli data could support global expansion.
Recorded Events
Jan 1, 2024: regulatory-designation
Jan 1, 2023: Funding milestone
Jan 1, 2022: Company milestone
Evidence Links
MSICS Pharma - MSX-06
company-website - MSICS Pharma - Jun 26, 2026 - Verified
Company site describes MSX-06, a naturally sourced GMP psilocybin product, as undergoing trials with hospitals for depression, OCD, anxiety, and eating disorders.
Israeli Startup Bets on Psychedelic Mushrooms for Mental Health
News / media - CTech by Calcalist - May 20, 2026 - Verified
Recent article reports MSICS is conducting Phase II trials for TRD and OCD and planning a multi-center PTSD trial with four Israeli hospitals.
Israeli Biotech Firm MSICS Raises $3.6M
News / media - Ynetnews - Apr 5, 2026 - Verified
Funding coverage says MSICS is conducting Phase 2 trials in Israel for TRD and OCD and plans a PTSD trial with four hospitals.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
CB Therapeutics
Discovery2 active candidates
shared compound: Psilocybinsame indication: Treatment-Resistant Depression (TRD)same regulator: other regulatorsimilar active pipeline size
Clairvoyant Therapeutics
Phase II1 active candidate
shared compound: PsilocybinPhase II peersimilar active pipeline sizeboth have forecast coverage
Diamond Therapeutics
Phase II1 active candidate2 trials
shared compound: PsilocybinPhase II peersimilar active pipeline sizeboth have forecast coverage
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Phase II
- Website
- Visit